Well 1 2 and three are unknown because MSB was directed to discontinue the trial. On balance I would put a Red Cross as not being met. If it was so clear, Novartis would have activated the deal. They haven’t.
piont 4 is patiently untrue. There are alternatives and moreover, there will be many more coming on stream very soon. As I have pointed out previously, other companies are not taking the slowly slowly approach. Rather, they are steaming ahead with unbelievable haste.
Finally, although it relates to the cancer application (which devotees love to mingle into discussion about other applications), the FDA dodgy approval of the Alzheimer’s treatment may well work against MSB by making them more conservative given the backlash.
Hope this assists you.
Growing Confidence on COVID-19 Application, page-20
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |